SME Times is powered by   
Search News
Just in:   • Tier 2 and 3 Indian cities to emerge as pivotal real estate growth hubs in 2025  • India’s Jaduguda Mines discovery extends uranium resources by over 50 years: Govt  • Australia 'excited to play' at inaugural Kho Kho World Cup   • Indian startup ecosystem raises over Rs 29,200 crore in 2024, witnesses record 13 IPOs  • K’taka govt employee digitally arrested for six hours, robbed of Rs 19 lakh 
Last updated: 24 Dec, 2024  

pharmacy.jpg Online pharmacy sector in India to see steady revenue growth next fiscal

pharmacy.jpg
   Top Stories
» Indian startup ecosystem raises over Rs 29,200 crore in 2024, witnesses record 13 IPOs
» Govt reforms, private partnerships behind Indian space industry growth in 2024: ISpA
» Indian firms raise bumper funds from equity market in 2024, set new records
» Centre-sponsored 10 plastic parks poised to spur exports, create more jobs
» India’s data centre capacity to more than double by 2027
IANS | 24 Dec, 2024

The online pharmacy sector in the country will see steady revenue growth next fiscal, reducing operating losses to below 10 per cent from over 30 per cent in fiscal 2023, by sharpening focus on high-margin product segments and operational efficiencies, a report showed on Tuesday.

E-pharmacies are eyeing sustainable growth by diversifying into high-margin segments such as wellness products and medical equipments, which are expected to comprise 40 per cent of sales next fiscal, up from about 30 per cent now and under 15 per cent in fiscal 2023.

“Players are also moving away from aggressive discounting to reduce key operating costs (discounting, delivery, distribution and employee — or DDDE) from around 65 per cent in fiscal 2023 to below 35 per cent next fiscal, which should help narrow losses and accelerate the move to profitability,” said Poonam Upadhyay, Director, CRISIL Ratings.

While the sector will see steady revenue growth, securing timely equity funding will be essential for two key reasons: one, to secure the capital needed to maximise growth opportunities arising from under-penetration; and two, to effectively manage cash burn while supporting credit profiles during the expansion phase.

According to the report, the e-pharmacy sector is in the early growth stage and faces significant operating losses due to high initial investments in technology, large inventory and supply chain inefficiencies.

Attracting customers in a fragmented market also entails substantial spending on marketing and discounts, leading to high customer acquisition cost.

Naren Kartic K, Associate Director, CRISIL Ratings, said that ongoing operating losses highlight the need for continued support from promoters, private equity investors and venture capitalists, as bank funding will be limited to working capital.

“As e-pharmacies expand operations and aim to reduce losses, they will still incur cash losses and likely require additional equity funds of Rs 2,300 crore over this and next fiscals, following over Rs 9,200 crore already secured since fiscal 2020,” he mentioned.

 
Print the Page
Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
84.35
82.60
UK Pound
106.35
102.90
Euro
92.50
89.35
Japanese Yen 55.05 53.40
As on 12 Oct, 2024
  Daily Poll
Will the new MSME credit assessment model simplify financing?
 Yes
 No
 Can't say
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter